Headquartered in Brisbane, CA Fiscal year ends December NASDAQ: CDNA caredx.com
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. It provides non-invasive, longitudinal molecular biomarker testing, digital health tools, and patient support solutions.
The business reports two revenue lines:
- **Testing Services:** Includes transplant surveillance tests such as AlloSure, and Specialty Oncology testing via NavDx, added through the July 1, 2026 acquisition of Naveris, Inc.
- **Patient and Digital Solutions:** Includes CareDx Pharmacy services, a patient portal, and EHR workflow integrations such as Epic Aura.
CareDx divested its Lab Products business on June 30, 2026 to concentrate on testing and services. Its pipeline includes AlloHeme, a cell therapy monitoring test targeted for a Q1 2027 launch, and HistoMap Kidney, a biopsy-based molecular test expected to see broader availability in 2027. Updated
Adjusted EBITDA guidance now runs $90 million to $100 million, up from $66 million to $78 million, a step change in profitability investors were not underwriting. Testing Services volume rose 51% year over year, helped by the Naveris deal that closed July 1.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. It provides non-invasive, longitudinal molecular biomarker testing, digital health tools, and patient support solutions.
The Wall Street consensus 12-month price target for CDNA is $82.00.
